Advanced

Could androgens protect middle-aged women from cardiovascular events? A population-based study of Swedish women: The Women's Health in the Lund Area (WHILA) Study

Khatibi Esfanjani, Ali LU ; Agardh, Carl-David LU ; Shakir, Yasameen LU ; Nerbrand, Christina LU ; Nyberg, Patrik LU ; Lidfeldt, Jonas LU and Samsioe, Göran LU (2007) In Climacteric 10(5). p.386-392
Abstract
Objective The aim of this analysis was to delineate perceived associations between androgens and cardiovascular events in perimenopausal women. Design A cross-sectional, population-based study of 6440 perimenopausal women aged 50-59 years, living in Southern Sweden. In all, 461 (7.1%) women were premenopausal (PM), 3328 (51.7%) postmenopausal without hormone therapy (HT) (PMO) and 2651 (41.2%) postmenopausal with HT (PMT). For further comparisons, 104 women (1.6%) who reported cardiovascular disease (CVD) were studied in detail; 49 had had a myocardial infarction, 49 a stroke and six women both events. For each woman with CVD, two matched controls were selected (n = 208). Results In the matched controlled series, androstenedione levels... (More)
Objective The aim of this analysis was to delineate perceived associations between androgens and cardiovascular events in perimenopausal women. Design A cross-sectional, population-based study of 6440 perimenopausal women aged 50-59 years, living in Southern Sweden. In all, 461 (7.1%) women were premenopausal (PM), 3328 (51.7%) postmenopausal without hormone therapy (HT) (PMO) and 2651 (41.2%) postmenopausal with HT (PMT). For further comparisons, 104 women (1.6%) who reported cardiovascular disease (CVD) were studied in detail; 49 had had a myocardial infarction, 49 a stroke and six women both events. For each woman with CVD, two matched controls were selected (n = 208). Results In the matched controlled series, androstenedione levels were lower (p < 0.005) in cases. Cases with hormone therapy had also lower testosterone levels than matched controls (p = 0.05). In the total cohort, by using multiple logistic regression analyses, testosterone was positively associated with low density lipoprotem cholesterol (p < 0.001) and high density lipoprotein cholesterol (HDL-C) (p < 0.001) in all women, but negatively associated with levels of triglycerides in both the PMO (p < 0.001) and PMT (p < 0.001) groups. Androstenedione levels were positively associated with HDL-C (p < 0.05) and negatively with triglycerides (p < 0.05) in the PM group. Conclusion Women with cardiovascular disease had lower serum androgen levels, particularly women using hormone replacement therapy, even when controlled for lipids and other potential risk factors. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
androstenedione, testosterone, high density lipoprotein cholesterol, lipoprotein cholesterol, sex hormone binding globulin, low density
in
Climacteric
volume
10
issue
5
pages
386 - 392
publisher
Taylor & Francis
external identifiers
  • wos:000250115300006
  • scopus:34548652777
ISSN
1369-7137
DOI
10.1080/13697130701377265
language
English
LU publication?
yes
id
1188d284-1b8c-4306-9d6c-0508a15afa15 (old id 655406)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17852141&dopt=Abstract
date added to LUP
2007-12-13 11:44:17
date last changed
2017-08-20 03:28:32
@article{1188d284-1b8c-4306-9d6c-0508a15afa15,
  abstract     = {Objective The aim of this analysis was to delineate perceived associations between androgens and cardiovascular events in perimenopausal women. Design A cross-sectional, population-based study of 6440 perimenopausal women aged 50-59 years, living in Southern Sweden. In all, 461 (7.1%) women were premenopausal (PM), 3328 (51.7%) postmenopausal without hormone therapy (HT) (PMO) and 2651 (41.2%) postmenopausal with HT (PMT). For further comparisons, 104 women (1.6%) who reported cardiovascular disease (CVD) were studied in detail; 49 had had a myocardial infarction, 49 a stroke and six women both events. For each woman with CVD, two matched controls were selected (n = 208). Results In the matched controlled series, androstenedione levels were lower (p &lt; 0.005) in cases. Cases with hormone therapy had also lower testosterone levels than matched controls (p = 0.05). In the total cohort, by using multiple logistic regression analyses, testosterone was positively associated with low density lipoprotem cholesterol (p &lt; 0.001) and high density lipoprotein cholesterol (HDL-C) (p &lt; 0.001) in all women, but negatively associated with levels of triglycerides in both the PMO (p &lt; 0.001) and PMT (p &lt; 0.001) groups. Androstenedione levels were positively associated with HDL-C (p &lt; 0.05) and negatively with triglycerides (p &lt; 0.05) in the PM group. Conclusion Women with cardiovascular disease had lower serum androgen levels, particularly women using hormone replacement therapy, even when controlled for lipids and other potential risk factors.},
  author       = {Khatibi Esfanjani, Ali and Agardh, Carl-David and Shakir, Yasameen and Nerbrand, Christina and Nyberg, Patrik and Lidfeldt, Jonas and Samsioe, Göran},
  issn         = {1369-7137},
  keyword      = {androstenedione,testosterone,high density lipoprotein cholesterol,lipoprotein cholesterol,sex hormone binding globulin,low density},
  language     = {eng},
  number       = {5},
  pages        = {386--392},
  publisher    = {Taylor & Francis},
  series       = {Climacteric},
  title        = {Could androgens protect middle-aged women from cardiovascular events? A population-based study of Swedish women: The Women's Health in the Lund Area (WHILA) Study},
  url          = {http://dx.doi.org/10.1080/13697130701377265},
  volume       = {10},
  year         = {2007},
}